Premium
Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas
Author(s) -
Lee Dakeun,
Suh YeonLim,
Park TaeIn,
Do InGu,
Seol Ho Jun,
Nam DoHyun,
Kim Sung Tae
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23249
Subject(s) - tetraspanin , medicine , radiology , surgery , biology , genetics , cell
Background Tetraspanin CD151 is a positive effector of cancer invasion and metastasis. Methods We investigated the expression of CD151 by immunohistochemistry in 211 cases of grade I to IV gliomas. Additionally, we performed O6‐methylguanin‐DNA methyltransferase (MGMT) methylation analysis using real‐time methylation‐specific PCR in 36 patients with glioblastoma, and the prognostic significance of these biomarkers in glioblastomas was evaluated. Results Overexpression of CD151 was observed in a significant proportion (55.6%) of glioblastomas, while CD151 was rarely overexpressed in most of grade I to III glial tumors. CD151 overexpression was closely associated with MGMT methylation ( P = 0.014), and it was a prognostic factor for predicting worse overall survival (OS; P = 0.002) and progression‐free survival (PFS; P = 0.043). We also found that combination of CD151 overexpression and MGMT methylation better stratified the patients' OS ( P = 0.001) and PFS ( P = 0.009). In multivariate analysis, CD151 overexpression was an independent prognostic factor for predicting OS over MGMT methylation ( P = 0.012). Conclusions CD151 seems to have a critical role for high‐grade progression in astroglial tumors. Furthermore, CD151 is a good tissue marker that can be used easily in a daily practice for predicting worse prognosis in patients with glioblastoma. J. Surg. Oncol. 2013;107:646–652. © 2012 Wiley Periodicals, Inc.